Literature DB >> 712208

Effects of glucocorticoids on osteoclast-activating factor.

M Strumpf, M A Kowalski, G R Mundy.   

Abstract

Glucocorticoids lower the serum calcium in patients with hypercalcemia due to myeloma and related lymphoproliferative disorders. OAF is a potent bone-resorbing lymphokine which is probably responsible for the bone lesions and hypercalcemia which occur in patients with these hematological neoplasms. In this study, we have examined the effects of cortisol on the production of OAF and its biological activity in order to clarify the mechanism of action of glucocorticoids in lowering the serum calcium in these disorders. The effects of OAF-containing media on bone resorption were inhibited by cortisol at concentrations from 10-5M to 10-9M. In contrast, OAF production was not inhibited by cortisol at concentrations less than 10-5M. These data support the hypothesis that glucocorticoids inhibit the effects of OAF in vivo primarily by a direct effect on bone resorption.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 712208

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  5 in total

1.  Effect of hydrocortisone on osteoclasts generated in cat bone marrow cultures.

Authors:  T Suda; N G Testa; T D Allen; D Onions; O Jarrett
Journal:  Calcif Tissue Int       Date:  1983       Impact factor: 4.333

2.  Treatment of hypercalcaemia associated with malignancy.

Authors:  R Wilkinson
Journal:  Br Med J (Clin Res Ed)       Date:  1984-03-17

Review 3.  The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma.

Authors:  E V McCloskey; J F Guest; J A Kanis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Production of bone-resorbing activity and colony-stimulating activity in vivo and in vitro by a human squamous cell carcinoma associated with hypercalcemia and leukocytosis.

Authors:  K Sato; H Mimura; D C Han; T Kakiuchi; Y Ueyama; H Ohkawa; T Okabe; Y Kondo; N Ohsawa; T Tsushima
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

Review 5.  [Hypocalcemia in malignant diseases].

Authors:  E Heidbreder; K Schafferhans; A Heidland
Journal:  Klin Wochenschr       Date:  1983-08-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.